NexgenRx Inc.
NXG.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.57% | 20.70% | 6.00% | 4.13% | 0.98% |
| Total Other Revenue | 0.65% | -444.49% | 185.92% | 94.12% | -28.78% |
| Total Revenue | 15.20% | 5.64% | 12.33% | 7.53% | -0.06% |
| Cost of Revenue | -9.89% | -36.92% | -16.02% | -4.88% | -0.45% |
| Gross Profit | 21.10% | 16.10% | 20.41% | 10.72% | 0.04% |
| SG&A Expenses | 3.63% | 12.09% | 7.83% | 3.36% | -0.46% |
| Depreciation & Amortization | -23.63% | -13.61% | 0.18% | -0.89% | -7.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -1.49% | -0.96% | 1.70% | 1.29% | -1.06% |
| Operating Income | 134.40% | 58.56% | 259.51% | 296.44% | 7.70% |
| Income Before Tax | 146.67% | 18.26% | 344.01% | 3,521.21% | 8.16% |
| Income Tax Expenses | -3.14% | 49.21% | 1.19% | 1.20% | 6.47% |
| Earnings from Continuing Operations | 140.48% | -558.38% | 291.41% | 996.57% | 7.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 140.48% | -558.38% | 291.41% | 996.57% | 7.43% |
| EBIT | 134.40% | 58.56% | 259.51% | 296.44% | 7.70% |
| EBITDA | 55.70% | 53.29% | 91.29% | 60.91% | 1.67% |
| EPS Basic | 152.08% | -146.15% | 300.00% | 1,100.00% | 6.67% |
| Normalized Basic EPS | 145.16% | 51.72% | 350.00% | 1,800.00% | 6.90% |
| EPS Diluted | 173.81% | -128.57% | 240.00% | 1,100.00% | -6.67% |
| Normalized Diluted EPS | 141.38% | 51.72% | 287.50% | 1,600.00% | 3.57% |
| Average Basic Shares Outstanding | 0.00% | 0.92% | 0.05% | 0.28% | 0.28% |
| Average Diluted Shares Outstanding | 0.43% | 0.92% | 18.53% | 0.00% | 5.49% |
| Dividend Per Share | -- | 0.00% | -- | -2.70% | -- |
| Payout Ratio | -0.57% | 0.84% | 1.98% | -0.91% | -0.13% |